Geron Investors Win Class Status in Bone Marrow Cancer Drug Suit

Geron Corp. investors who say the company misled them about a bone marrow cancer drug trial may pursue their securities fraud allegations as a class, a federal judge in California said.

The now-certified class covers investors who purchased Geron common stock from March 19, 2018, through Sept. 26, 2018, and lost money as a result, with exceptions for those with certain close ties to the biotechnology company, the U.S. District Court for the Northern District of California said.

At least 100 unique account holders purchased Geron stock during the class period, and the company admitted it sold more than ...